newsfilter
← Latest News
GlobeNewswire·

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4